Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
51
PROK Quote, Financials, Valuation and Earnings
Last price:
$3.33
Seasonality move
:
-23.87%
Day range:
$3.52 - $4.05
52-week range:
$0.46 - $7.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
7.5M
Avg. volume:
25.3M
1-year change:
53.04%
Market cap:
$456M
Revenue:
$76K
EPS (TTM):
-$0.60
Analysts' Opinion
-
Consensus RatingProKidney has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.60, ProKidney has an estimated upside of 59.09% from its current price of $3.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 71.59% downside risk from its current price of $3.52.
Fair Value
-
According to the consensus of 6 analysts, ProKidney has 59.09% upside to fair value with a price target of $5.60 per share.
PROK vs. S&P 500
-
Over the past 5 trading days, ProKidney has underperformed the S&P 500 by -32.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ProKidney does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProKidney has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ProKidney reported revenues of $230K.
Earnings Growth
-
ProKidney has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ProKidney reported earnings per share of -$0.13.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-17994.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $230K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$127.4M | -$150.7M | -$185M | -$40.1M | -$41.4M | |
| EBITDA | -$113M | -$125M | -$160.1M | -$34.1M | -$35.8M | |
| Diluted EPS | -$0.75 | -$0.57 | -$0.60 | -$0.16 | -$0.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $35.2M | $480.1M | $340.2M | $359.7M | |
| Total Assets | -- | $53.5M | $495.2M | $387.8M | $406.1M | |
| Current Liabilities | -- | $31.9M | $11.3M | $19.3M | $32.8M | |
| Total Liabilities | -- | $33.3M | $14.2M | $24.7M | $36.1M | |
| Total Equity | -- | $20.2M | $481M | $363M | $370M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87.6M | -$98.7M | -$121.3M | -$34.6M | -$29.6M | |
| Cash From Investing | -$193.5M | -$79M | -$9.7M | $58.4M | $28.3M | |
| Cash From Financing | $523M | -$9.6M | $144.4M | -$13K | -$12K | |
| Free Cash Flow | -$89.6M | -$132.9M | -$151M | -$35.6M | -$30.7M | |
PROK
Sector
Market Cap
$456M
$35.2M
Price % of 52-Week High
49.37%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
53.04%
-36.85%
Beta (5-Year)
--
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.01
200-day SMA
Buy
Level
$1.43
Bollinger Bands (100)
Buy
Level
0.21 - 1.99
Chaikin Money Flow
Sell
Level
-115.5M
20-day SMA
Buy
Level
$1.99
Relative Strength Index (RSI14)
Buy
Level
63.87
ADX Line
Buy
Level
33.24
Williams %R
Neutral
Level
-54.78
50-day SMA
Buy
Level
$1.28
MACD (12, 26)
Buy
Level
1.05
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
554.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.7667)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Stock Forecast FAQ
In the current month, PROK has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PROK average analyst price target in the past 3 months is $5.60.
-
Where Will ProKidney Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProKidney share price will rise to $5.60 per share over the next 12 months.
-
What Do Analysts Say About ProKidney?
Analysts are divided on their view about ProKidney share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProKidney is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is ProKidney's Price Target?
The price target for ProKidney over the next 1-year time period is forecast to be $5.60 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PROK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProKidney is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of PROK?
You can purchase shares of ProKidney via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProKidney shares.
-
What Is The ProKidney Share Price Today?
ProKidney was last trading at $3.33 per share. This represents the most recent stock quote for ProKidney. Yesterday, ProKidney closed at $3.52 per share.
-
How To Buy ProKidney Stock Online?
In order to purchase ProKidney stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 4.61% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.03% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 9.69% over the past day.
